Correspondence 0001140361-24-035029 from Grace Therapeutics, Inc. (GRCE) (CIK 0001444192) (GRCE)

Grace Therapeutics, Inc. (GRCE) (CIK 0001444192)
Date: July 31, 2024 · CIK: 0001444192 · Accession: 0001140361-24-035029

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-280536

Date

July 31, 2024

Author

/s/ Prashant Kohli

Form

CORRESP

Company

Grace Therapeutics, Inc. (GRCE) (CIK 0001444192)

Letter

Office of Life Sciences Division of Corporation Finance Attention: Daniel Crawford Re: Acasti Pharma Inc. Registration Statement on Form S-4 (File No. 333-280536) Request for Acceleration of Effective Date

Dear Mr. Crawford:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Acasti Pharma Inc. (the “Company”) hereby respectfully requests that the U.S. Securities and Exchange Commission accelerate the effective date and time of the above referenced Registration Statement on Form S-4 (the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m. Eastern Time on August 2, 2024, or as soon thereafter as practicable.

The Company requests that it be notified of such effectiveness by a telephone call to Steven Abrams of Hogan Lovells US LLP at (267) 675-4671.

[Signature page follows]

Sincerely,
Acasti Pharma Inc.

Show Raw Text

CORRESP
1
filename1.htm

    July 31, 2024

    CORRESPONDENCE FILED VIA EDGAR

    Office of Life Sciences

    Division of Corporation Finance

    U.S. Securities and Exchange Commission

    100 F Street, N.E.

    Washington, D.C. 20549

    Attention: Daniel Crawford

            Re:

            Acasti Pharma Inc.

              Registration Statement on Form S-4 (File No. 333-280536)

              Request for Acceleration of Effective Date

    Dear Mr. Crawford:

    Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Acasti Pharma Inc. (the “Company”) hereby respectfully
      requests that the U.S. Securities and Exchange Commission accelerate the effective date and time of the above referenced Registration Statement on Form S-4 (the “Registration Statement”) and declare the
      Registration Statement effective as of 4:00 p.m. Eastern Time on August 2, 2024, or as soon thereafter as practicable.

    The Company requests that it be notified of such effectiveness by a telephone call to Steven Abrams of Hogan Lovells US LLP at (267) 675-4671.

    [Signature page follows]

            Sincerely,

            Acasti Pharma Inc.

            /s/ Prashant Kohli

            Prashant Kohli

            Chief Executive Officer and Director

SecProbe.io